



#818
MB
05/08/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 18733/1002

In re patent application of

Hans J. HANSEN

Serial No. 09/688,089

Group Art Unit: 1642

Filed: October 16, 2000

Examiner: S. HUFF

For: MULTI-STAGE CASCADE BOOSTING VACCINE

AMENDMENT AND REQUEST FOR RECONSIDERATION
UNDER 37 C.F.R. § 1.111

RECEIVED
MAY 06 2002
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Response filed: April 26, 2002

Sir:

This is a response to the Office Action mailed October 26, 2001, in the above-identified application. A response is due on April 26, 2002, by virtue of the attached Petition for Extension of Time and payment of the required fees. Although applicant believes that the amount of the attached check is correct, the Commissioner is hereby authorized to credit any overpayment or to charge any deficiency to Deposit Account No. 19-0741. Please amend the application as follows:

IN THE SPECIFICATION

Please substitute the paragraph bridging pages 13 and 14 of the specification with the following paragraph. A marked-up copy showing the changes made is attached.

B'
mb
C1

An example of a suitable Mab is a Class III anti-CEA Mab. Conventional antisera raised against CEA usually contain antibodies that react with a group of substances closely related to CEA. The major members of this family of CEA-related antigens are (1) the normal cross-reactive antigen (NCA), which shares a similar tissue distribution with CEA, and (2) meconium antigen (MA), which shares almost identical physiochemical properties with CEA. The first panel of monoclonal antibodies (MAb) that defined NCA-cross-reactive, MA-cross-reactive, and CEA-specific epitopes on the CEA molecule were described by Primus *et al.*, *Cancer Research* 43: 686 (1983). In particular, three classes of anti-CEA